This study shows the benefit of reducing waiting time between acute events and intervention in patients with severe symptomatic carotid stenosis. Its outcomes support the efforts to reduce patient management. Moreover, it could be used as an indicator of clinical practice quality. The risk of recurrent events after an ischemic event is significantly higher in<a href="https://solaci.org/en/2018/10/12/effect-of-more-expedited-carotid-intervention-on-recurrent-events/" title="Read more" >...</a>
The systematic reduction of inefficiencies in the catheterization laboratory (such as the improvement of lab room start times and room turnaround times) can definitely improve the productivity of a Department of Interventional Cardiology without forcing its members to stay in the facilities longer. As a matter of fact, work can be finished even faster with<a href="https://solaci.org/en/2018/03/14/keys-to-productivity-improvement-in-the-cath-lab/" title="Read more" >...</a>
The recent publication of several reports on risk of cataract, left sided brain tumors, subclinical atherosclerosis and chromosome damage among interventional cardiologists has raised increasing concerns about radiation exposure in the cath lab. Recognizing these risks has created a demand of these new forms of protection. Unfortunately, these have mainly been focused on the main operator,<a href="https://solaci.org/en/2017/11/15/study-confirms-lead-shields-protect-cath-lab-staff-from-radiation-exposure/" title="Read more" >...</a>
Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of patients with severe aortic stenosis (AS). Randomized studies have shown the benefits of TAVR in patients at prohibitive surgical risk, as well as high and intermediate risk. The NOTION trial (Nordic Aortic Valve Intervention Trial) randomized patients with low risk severe AS to TAVR and<a href="https://solaci.org/en/2024/05/28/tavr-vs-savr-in-los-risk-patients-10-year-outcomes-of-the-notion-trial/" title="Read more" >...</a>
A lesion ≥50% in the left main coronary artery (LMCA) is considered severe, according to various scientific societies, regardless of the presence of symptoms or ischemia, due to the extent of myocardium at risk. In such cases, revascularization is indicated. In many patients, lesions in this section of the coronary artery have severe calcification, which<a href="https://solaci.org/en/2024/03/13/lithotripsy-in-the-left-main-coronary-artery/" title="Read more" >...</a>
Aortic stenosis (AS) is a progressive disease associated with morbidity and mortality, especially in severe cases. However, recent studies have revealed that moderate stenosis can also have unfavorable consequences in the course of the disease. One of the challenges lies in that determining its severity is sometimes difficult due to discrepancies between valve area, gradient,<a href="https://solaci.org/en/2023/12/04/is-as-only-important-when-severe/" title="Read more" >...</a>
There is no question as regards the recommended treatment for symptomatic severe aortic stenosis, seeing as both transcatheter and surgical aortic valve replacement (TAVR and SAVR) have shown to significantly improve prognosis. This is despite the fact that there is still certain ambiguity around its characterization, which looks to define it according to hemodynamic severity<a href="https://solaci.org/en/2023/11/30/low-gradient-normal-flow-aortic-stenosis-changes-in-quality-of-life-with-tavr/" title="Read more" >...</a>
At present, surgical aortic valve replacement (SAVR) uses bioprostheses. However, when these fail, we are presented with a great challenge, seeing as repeat SAVR involves a higher risk. In this context, valve-in-valve (V-in-V TAVR) has surged as a very attractive alternative. Bioprosthesis fracture (BPF) is a new interesting strategy that has shown lower gradient and<a href="https://solaci.org/en/2023/03/28/when-is-it-best-to-fracture-a-bioprosthesis-in-tavr/" title="Read more" >...</a>
There are many current randomized trials comparing percutaneous coronary intervention (PCI) with myocardial revascularization surgery (MRS) for the treatment of left main coronary artery disease (LMCAD). In the European Society of Cardiology guidelines, PCI is classified as Ia (LMCAD with low-complexity coronary disease) or IIa indication (intermediate complexity), whereas, according to the American Heart Association<a href="https://solaci.org/en/2023/01/11/real-world-revascularization-strategy-for-left-main-coronary-artery-surgery-or-pci/" title="Read more" >...</a>
About 4% of the population suffers from tricuspid regurgitation (TR). This disease is associated with hard-to-manage heart failure (HF)—often requiring hospitalization—and with mortality. Surgery in this valve is not simple and has high morbidity and mortality rates due to its comorbidities. Currently, a percutaneous strategy for its resolution is under development, but we still do<a href="https://solaci.org/en/2022/07/21/tricuspid-regurgitation-edge-to-edge-treatment-with-pascal/" title="Read more" >...</a>